Mylan (MYL) Downgraded by TheStreet to C+
Mylan (NASDAQ:MYL) was downgraded by investment analysts at TheStreet from a “b-” rating to a “c+” rating in a research report issued to clients and investors on Friday.
Other equities analysts also recently issued research reports about the company. Goldman Sachs Group boosted their price target on Mylan from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, January 11th. Royal Bank of Canada upped their target price on Mylan from $32.00 to $37.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 7th. Leerink Swann assumed coverage on Mylan in a research report on Tuesday, January 2nd. They issued a “market perform” rating and a $44.00 target price on the stock. Citigroup reaffirmed a “buy” rating and issued a $58.00 target price (up previously from $48.00) on shares of Mylan in a research report on Thursday, January 4th. Finally, Wells Fargo & Co set a $43.00 target price on Mylan and gave the company a “hold” rating in a research report on Thursday, January 18th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $44.65.
Mylan (NASDAQ:MYL) opened at $40.60 on Friday. The firm has a market capitalization of $21,071.22, a P/E ratio of 25.22, a price-to-earnings-growth ratio of 1.06 and a beta of 1.35. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan has a 12-month low of $29.39 and a 12-month high of $47.82.
Several hedge funds have recently modified their holdings of MYL. Pzena Investment Management LLC boosted its stake in shares of Mylan by 84.1% in the third quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock valued at $712,770,000 after buying an additional 10,381,697 shares during the period. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Mylan in the fourth quarter valued at approximately $137,023,000. Schroder Investment Management Group boosted its stake in shares of Mylan by 74.7% in the third quarter. Schroder Investment Management Group now owns 3,026,172 shares of the company’s stock valued at $93,388,000 after buying an additional 1,294,400 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Mylan by 30.3% in the fourth quarter. Bank of New York Mellon Corp now owns 5,334,789 shares of the company’s stock valued at $225,715,000 after buying an additional 1,239,089 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in Mylan by 72.9% during the fourth quarter. Wells Fargo & Company MN now owns 2,560,305 shares of the company’s stock worth $108,326,000 after purchasing an additional 1,079,696 shares during the last quarter. Institutional investors and hedge funds own 75.56% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2018/02/13/mylan-myl-downgraded-by-thestreet-to-c.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.